Abstracts Archive - Page 1332 of 2607 - ACR Meeting Abstracts

Abstract Number: 2186 • 2018 ACR/ARHP Annual Meeting
Process Evaluation of a Culturally-Sensitive, Community Based Self-Management Program for First Nations People with Arthritis and Their Families
Diane Lacaille¹, June Kaminski², Jade Collison³, Linda Lavender⁴, Monica Brown⁵, Kim Roberts⁶, Deborah Da Costa⁷, Paul Adam⁸, Linda Li² and Allen Lehman⁹, ¹Arthritis Research Canada/University of British Columbia, Medicine/Rheumatology, Richmond, BC, Canada, ²Arthritis Research Canada, Richmond, BC, Canada, ³Haida Health Centre, Old Massett, BC, Canada, ⁴Kwakiutl District Council Health Services, Campbell River, BC, Canada, ⁵Director, Haida Health Centre, Old Massett, BC, Canada, ⁶Director, Kwakiutl District Council Health Services, Campbell River, BC, Canada, ⁷Medicine, McGill University, Montreal, QC, Canada, ⁸Mary Pack Arthritis Program, Vancouver, BC, Canada, ⁹Senior Medical Scientific Liaison-Rheumatology, Janssen, Pharmaceutical Companies of Johnson and Johnson, Vancouver, BC, Canada
Background/Purpose: First Nation community consultations identified arthritis as a priority health concern and the need for culturally sensitive health services adapted to community needs. In…
Abstract Number: 2187 • 2018 ACR/ARHP Annual Meeting
Specialist Link Telephone Advice Cost Effectively Enhances Rheumatology Patient Care in Alberta, Canada
Yolanda Martens-Vanhilst¹, Dianne P. Mosher², Linda Slocombe¹ and Paul MacMullan³, ¹University of Calgary, Calgary, AB, Canada, ²Med, University of Calgary, Calgary, AB, Canada, ³Medicine, Division of Rheumatology, University of Calgary, Calgary, AB, Canada
Background/Purpose: The Calgary zone of Alberta Health Services serves a population of almost 2million Canadians over a wide geographical area and is underserved in terms…
Abstract Number: 2188 • 2018 ACR/ARHP Annual Meeting
Regional Analysis of Impact of Participation in a Patient Support Program on Clinical Outcomes Among Patients with Rheumatoid Arthritis Receiving Adalimumab (Humira)
Filip van Den Bosch¹, Andrew Ostor², Patrick Zueger³, Meijing Wu³, Ivan Lagunes Galindo³ and Siegfried Wassenberg⁴, ¹Ghent University Hospital, Ghent, Belgium, ²Cabrini Medical Center, Melbourne, Australia, ³AbbVie Inc., North Chicago, IL, ⁴Rheumazentrum Ratingen, Ratingen, Germany
Background/Purpose: Patients (pts) receiving adalimumab for RA or other indications are offered participation in the AbbVie pt support program (PSP). This analysis assessed clinical outcomes…
Abstract Number: 2189 • 2018 ACR/ARHP Annual Meeting
Use of Smartphones in Collecting Patient Reported Outcomes (PROs): Feasibility of a Study Nested in a US National Cohort
Kaleb Michaud^1,2, Sofia Pedro², Madison Grinnell¹ and Rebecca Schumacher², ¹Rheumatology, University of Nebraska Medical Center, Omaha, NE, ²FORWARD, The National Databank for Rheumatic Diseases, Wichita, KS
Background/Purpose: Multiple small studies have demonstrated that patients with rheumatic disease can and are willing to use smartphones to track disease severity. The objective of…
Abstract Number: 2190 • 2018 ACR/ARHP Annual Meeting
Means of Collaboration between Ophthalmologists, Rheumatologists and Internists in the Management of Non-Infectious Uveitis: A Nationwide Study
Magali Pacanowski Fournier¹, Antoine Brezin², Christophe Chiquet Sr.³, David Saadoun⁴, Jeremie Sellam⁵, Patrice Cacoub⁶, Pascal Sève⁷, Bahram Bodaghi Sr.⁸ and Laurent Kodjikian Sr.^9,10,11, ¹medical department, Magali Pacanowski Fournier is employee of AbbVie and own AbbVie stock, Rungis, France, ²Ophtalmology, Referral Center for Rare Ophthalmological Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, ophtalmology, France, Paris, France, ³ophtalmology, CHU-Grenoble-Alpes, La Tronche, France, ⁴Sorbonne Universités, UPMC Univ Paris 06, UMR 7211, and Inflammation-Immunopathology-Biotherapy Department (DHU i2B), F-75005, Paris, France; INSERM, UMR_S 959, F-75013, Paris, France; CNRS, FRE3632, F-75005, Paris, France; AP-HP, Groupe Hospitalier, Paris, France, ⁵AP-HP Saint-Antoine hospital, Service de Rhumatologie, Inserm UMRS_938, Paris, France, ⁶Internal Medicine Department, University Hospital “Pitié-Salpêtrière”, “Pierre et Marie Curie Paris VI” University, Paris, France, Paris, France, ⁷Internal medicine, Internal medicine department, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, Lyon, France, ⁸ophtalmology, Hôpital La Pitié-Salpêtrière; Université Sorbonne, paris, France, ⁹ophtalmology, Chu de La Croix-Rousse, hospices civils de Lyon, Lyon, France, ¹⁰université Claude Bernard lyon 1, villeurbanne, France, ¹¹UMR-CNRS 5510 Matéis, villeurbanne, France
Background/Purpose: When uveitis is believed to be part of an underlying systemic disease or when a systemic treatment is required, a multi-disciplinary approach is usually…
Abstract Number: 2191 • 2018 ACR/ARHP Annual Meeting
Safety of Ultrasound-Guided Injections Using Local Puncture Site Sterility
Suzan Jaradat¹, Maheswari Muruganandam², Noelle Rolle², Wilmer Sibbitt Jr.³, William Hayward⁴, N. Suzanne Emil³, Monthida Fangtham³, Roderick Fields³ and Arthur Bankhurst³, ¹Internal Medicine, University of New Mexico Health Sciences Center, ALBUQUERQUE, NM, ²University of New Mexico Health Sciences Center, ALBUQUERQUE, NM, ³Rheumatology, University of New Mexico Health Sciences Center, Albuquerque, NM, ⁴The Department of Exercise and Sport Sciences, New Mexico Highlands University, Las Vegas, NM
Background/Purpose: Ultrasound (US)-guided injections in musculoskeletal medicine typically utilize either local puncture site sterility or conventional surgical sterility. We report on the safety and complications…
Abstract Number: 2192 • 2018 ACR/ARHP Annual Meeting
User Experience with Methotrexate in Managing Inflammatory Arthritis Under the Support of an Interprofessional Arthritis Care Team (UMTX Study)
Diane Tin¹, Marie Craig¹, Carolyn Dittmar², Carter Thorne², Nooshin Samadi¹, Edward Ng² and Aubrey Michael², ¹The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, ²Southlake Regional Health Centre, Newmarket, ON, Canada
Background/Purpose: Methotrexate (MTX) is the cornerstone for the treatment of RA as monotherapy or in combination. While its cost effectiveness in halting the disease is…
Abstract Number: 2193 • 2018 ACR/ARHP Annual Meeting
Online Direct-to-Patient Recruitment for Systemic Lupus Erythematosus Results in Rapid Enrollment
June Fujimoto, Lilian Borisov, Kristen Warren and Robert Terbrueggen, DxTerity, Rancho Dominguez, CA
Background/Purpose: For precision medicine to address the dynamic nature of autoimmune diseases, more frequent measurements of disease activity and therapy response are needed. We report…
Abstract Number: 2194 • 2018 ACR/ARHP Annual Meeting
Develop a New Platform for Post-Marketing Vigilance Though Smart System of Disease Management (SSDM) Mobiles Tools: A Real World Cohort Study of RA Patients from China
Yongfu Wang¹, Hua Wei², Jing Yang³, Chun Li⁴, Rong Mu⁵, Bin Wu⁶, Hongzhi Wang⁷, Yong Wang⁸, Xiaohan Wang⁹, Huifang Guo¹⁰, Jing Xue¹¹, Jinli Ru¹², Xiafei Xin¹³, Fengxiao Zhang¹⁴, Lirong Kang¹, Hong Liu³, Xiaoling Liu¹⁵, Tong Xie¹⁶, Lingxun Shen¹⁷, Huiqin Yang¹⁸, Shouxin Li¹⁹, Fen Li²⁰, Fen Wang²¹, Rui Wu²², Yuan Liu²³, Hui Xiao²³, Yuhua Jia²³, Fei Xiao²³ and Jianlin Huang²⁴, ¹The First Affiliated Hospital of BaoTou Medical College, Baotou, China, ²Northern Jiangsu People's Hospital, Yangzhou, China, ³Department of rheumatology, Central Hospital of MianYang, Sichuan, Mian Yang, China, ⁴Peking University People's Hospital, Beijing, China, ⁵Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China, ⁶Department of Rheumatology, Chongqing Hospital of Traditional Chinese Medicine, Chongqing, China, ⁷The First Hospital of Jiaxing, Jiaxing, China, ⁸The first Hospital Affiliated to AMU (Southernwest Hospital), Chongqing, China, ⁹Department of Rheumatology and Immunology, Anyang district hospital, Anyang, China, ¹⁰The Second Hospital of Hebei Medical University, Shijiazhuang, China, ¹¹88 Jiefang Road, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China, ¹²The Second hospital of Shanxi Medical University, Taiyuan, China, ¹³Department of Rheumatology and Immunology, NingBo First Hospital, Zhejiang, Ningbo, China, ¹⁴Department of Rheumatology and Immunology, Hebei General Hospital, Shijiazhuang, China, ¹⁵The 1st Affiliated Hospital of Guangzhou University of TCM, Guangzhou, China, ¹⁶Affiliated hospital of Guangdong medical University, Zhanjiang, China, ¹⁷Union Hospital Tongji Medical College of Huazhong University of Science and Technology, Wuhan, China, ¹⁸Wuhan No 1 Hospital, wuhan, China, ¹⁹Tongji Hospital，Tongji Medical College，Huazhong University of Science and Technology, wuhan, China, ²⁰The Second Xiangya Hospital of Central South University, Changsha, China, ²¹Department of Rheumatology, First Affiliated Hospital of Medical University Of Anhui, Hefei, China, ²²The First Affiliated Hospital of Nanchang University, Nanchang, China, ²³Shanghai Gothic Internet Technology Co., Ltd., Shanghai, China, ²⁴Department of rheumatology, The Sixth Hospital Affiliated to Sun yat-sen University, Guangzhou, China
Background/Purpose: Adverse events (AE) during treatment in RA patients are unavoidable. Monitoring AEs in real time during long-term treatment is critical for AE detection and…
Abstract Number: 2195 • 2018 ACR/ARHP Annual Meeting
Predictive Factors of a Positive PET/CT Scan for Vascular Involvement in Patients with Polymyalgia Rheumatica
Diana Prieto Peña¹, Monica Calderón Goercke¹, Javier Loricera², Isabel Martínez-Rodríguez³, Ignacio Banzo³, Belén Atienza-Mateo⁴, José Luis Martín-Varillas⁴, Vanesa Calvo-Río¹, Carmen Gonzalez Vela⁵, Alfonso Corrales⁴, Santos Castañeda⁶, Ricardo Blanco⁴, José Luis Hernández² and Miguel Angel González-Gay⁷, ¹Rheumatology, Rheumatology. Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ²Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ³Nuclear Medicine, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ⁴Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ⁵Pathology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ⁶Rheumatology, Rheumatology Department, Hospital Universitario la Princesa, IIS-Princesa, Madrid, Spain, ⁷Hospital Universitario Marqués de Valdecilla, University of Cantabria Santander, Santander, Spain
Background/Purpose: Polymyalgia rheumatica (PMR) is often the presenting manifestation of giant cell arteritis (GCA). Fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) scan often discloses the presence…
Abstract Number: 2196 • 2018 ACR/ARHP Annual Meeting
Kinetics of Tissue-Specific Distribution of 18f-Fluorodeoxyglucose in Positron Emission Tomography in Large Vessel Vasculitis
Joel S. Rosenblum¹, Kaitlin Quinn², Mark A. Ahlman³ and Peter C. Grayson⁴, ¹NIAMS, National Institute of Arthritis, Musculoskeletal and Skin Disease (NIAMS), Bethesda, MD, ²Systemic Autoimmunity Branch, NIAMS, Bethesda, MD, ³Radiology and Imaging Sciences, National Institutes of Health, Bethesda, MD, ⁴National Institute of Arthritis, Musculoskeletal and Skin Disease, National Institutes of Health, Bethesda, MD
Background/Purpose: 18F-fluorodeoxyglucose (FDG) PET may be used to quantify vascular inflammation in large-vessel vasculitis (LVV). Quantitative analysis of arterial FDG uptake has not been standardized. Delayed…
Abstract Number: 2197 • 2018 ACR/ARHP Annual Meeting
Steroid Bolus Leads to a Negative 18f-FDG PET/CT Scan in Large Vessel Vasculitis. Data from a Multicenter Giant Cell Arteritis Cohort Database
Paula Estrada¹, Patricia Moya², Hector Corominas³, Delia Reina⁴, Dacia Cerdà⁴, Daniel Roig Vilaseca⁴, Vanessa Navarro⁴, Sergi Heredia⁴ and Francisco Javier Narváez⁵, ¹Rheumatology, Hospital Moisès Broggi-Hospital General de L´Hospitalet. Consorci Sanitari Integral, Barcelona, Spain, ²Rheumatology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ³Rheumatology, Hospital Universitari de la Santa Creu i Sant Pau, Barcelona, Spain, ⁴Rheumatology, Hospital Moisès Broggi-Hospital General de L´Hospitalet. Consorci Sanitari Integral,, barcelona, Spain, ⁵Rheumatology Department, Hospital de Bellvitge. Barcelona. Spain, L’Hospitalet de Llobregat, Spain
Background/Purpose: Giant cell arteritis (GCA) and polymialgia rheumatica (PMR) are overlapping inflammatory diseases. Large Vessel Vasculitis (LVV) is frequently present in any of the two…
Abstract Number: 2198 • 2018 ACR/ARHP Annual Meeting
Evaluation of 18F-Fluorodeoxyglucose PET-CT Score at Baseline on the Therapeutic Response to Prednisone in Polymyalgia Rheumatica: A Retrospective Study
Nicolas Giraud¹, Maxime Sondag², Aline Charpentier², Hatem Boulahdour³, Clément Prati^4,5, Daniel Wendling^6,7 and Frank Verhoeven⁸, ¹Rheumatology, CHU de Besançon, Besançon, France, ²rheumatology, CHU de Besançon, Besancon, France, ³CHU de Besançon, Besançon, France, ⁴EA 4267 FDE, FHU INCREASE, Université de Bourgogne Franche Comté, Besancon, France, ⁵Rheumatology, University Hospital - Bourgogne Franche Comté University, Besancon, France, ⁶Rheumatology, University Hospital - Bourgogne Franche Comté University, Besançon, France, ⁷EA 4266, Univ. Bourgogne Franche-Comté, F-25000 Besançon, France, F-25000 Besançon, France, ⁸EA 4267 PEPITE, Université de Bourgogne Franche Comté, Besançon, France
Background/Purpose: To evaluate the impact of 18F-fluorodeoxyglucose PET-CT (FDG-PET/CT) score at baseline, on the therapeutic response to prednisone, in patients with polymyalgia rheumatica (PMR). Methods:…
Abstract Number: 2199 • 2018 ACR/ARHP Annual Meeting
Active Disease and Follow up 18f-FDG-PET/CT in Patients with Giant Cell Arteritis. Which Treatment Is More Likely to Achieve Remission?
Verena Schönau¹, Georg Schett², Matthias Englbrecht¹, Juergen Rech³ and Jessica Roth¹, ¹Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany, ²Friedrich-Alexander-University Erlangen-Nuremberg (FAU), Department of Internal Medicine 3 – Rheumatology and Immunology, University Hospital Erlangen, Erlangen, Germany, ³Department of Internal Medicine 3, University of Erlangen-Nuremberg, Erlangen, Germany, Erlangen, Germany
Background/Purpose: Giant cell arteritis is the most common large vessel vasculitis. 18F-FDG-PET/CT is known to be a useful imaging technique for diagnosing giant cell arteritis.…
Abstract Number: 2200 • 2018 ACR/ARHP Annual Meeting
Does an 18f-FDG-PET/CT in Patients with Giant Cell Arteritis in Clinical Remission Make Sense?
Verena Schönau¹, Jessica Roth¹, Matthias Englbrecht¹, Juergen Rech² and Georg Schett³, ¹Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany, ²Department of Internal Medicine 3, University of Erlangen-Nuremberg, Erlangen, Germany, Erlangen, Germany, ³Friedrich-Alexander-University Erlangen-Nuremberg (FAU), Department of Internal Medicine 3 – Rheumatology and Immunology, University Hospital Erlangen, Erlangen, Germany
Background/Purpose: Giant cell arteritis is the most common large vessel vasculitis. 18F-FDG-PET/CT is known to be a useful imaging technique for diagnosing giant cell arteritis.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].